MDP301 Phase III trial of PRO 2000 vaginal microbicide
gel- results announced.
The phase III MDP301 trial evaluated the vaginal microbicide gel
PRO2000 against a placebo gel for safety and effectiveness in
reducing the risk of HIV transmission. It is the largest vaginal
microbicide trial to date and was conducted in six research centres
in South Africa, Tanzania, Uganda and Zambia. The study found
no evidence that the vaginal
microbicide, PRO 2000, reduces the risk of HIV infection in
women.
The MRC Clinical Trials Unit was involved in
the design, co-ordination, data management, and analysis of the
trial.
The Microbicides Development Programme (MDP)
is a not-for-profit, African-European partnership, which was
established to develop vaginal microbicides to reduce the risk of
HIV infection in women. MDP is funded by the UK government
through the Department for International Development (DFID) and the
MRC, and managed jointly by Imperial College, London and the MRC
Clinical Trials Unit.
For more information on the Microbicides
Development Programme and the MDP301 trial results please refer to
the MDP website:
http://www.mdp.mrc.ac.uk/index.html
